Bavarian Nordic secures $156.8m US vaccine deal
BARDA is a part of the Administration for Strategic Preparedness and Response within the US Department of Health and Human Services. The product, which represents $139.7m of the
The US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for Bavarian Nordic's chikungunya virus vaccine candidate, CHIKV VLP, granting it priority review status.
The territories include Japan, South Korea, and several Southeast Asian countries, including Vietnam, Thailand, Malaysia, the Philippines, Singapore, and Indonesia. CBT-001 is an investigational emulsified nintedanib ophthalmic formulation